BTIG analyst Julian Harrison maintained a Buy rating on Tvardi Therapeutics yesterday and set a price target of $15.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Julian Harrison has given his Buy rating due to a combination of factors that highlight Tvardi Therapeutics’ promising pipeline and financial stability. The company’s development of TTI-109, a pro-drug of TTI-101, shows potential for improved tolerability due to its higher bioavailability and reduced gastrointestinal side effects. This could address the previous challenges faced by TTI-101 in treating idiopathic pulmonary fibrosis (IPF) and open opportunities for expanding into other STAT3-driven indications.
Furthermore, Tvardi’s ongoing trials for TTI-101 in hepatocellular carcinoma (HCC) have demonstrated meaningful clinical activity, both as a standalone treatment and in combination with other cancer therapies. The unmet need in HCC, particularly due to low response rates with current standard-of-care treatments, presents a compelling case for TTI-101’s potential. Additionally, Tvardi’s strong cash position, with sufficient funds to support operations into the fourth quarter of 2026, provides a solid financial foundation for advancing their clinical programs.
TVRD’s price has also changed dramatically for the past six months – from $26.350 to $4.030, which is a -84.71% drop .